Recent News

• 11.03.2025 - 2025 Q3 Earnings Call
• 11.03.2025 - 2025 Q3 Earnings Call
• 08.04.2025 - 2025 Q2 Earnings Call
• 08.04.2025 - 2025 Q2 Earnings Call
• 06.12.2025 - BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
• 06.12.2025 - BioNTech kündigt strategische Transaktion zur Übernahme von CureVac im Rahmen eines öffentlichen Umtauschangebots an
• 06.12.2025 - BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
• 06.02.2025 - BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
• 06.02.2025 - BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
• 06.02.2025 - BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt

Recent Filings

• 06.12.2025 - EX-99.1 EX-99.1
• 06.12.2025 - 425 Prospectuses and communications, business combinations
• 06.12.2025 - 425 Prospectuses and communications, business combinations
• 06.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.12.2025 - 425 Prospectuses and communications, business combinations
• 06.12.2025 - 425 Prospectuses and communications, business combinations
• 06.12.2025 - 425 Prospectuses and communications, business combinations
• 06.04.2025 - 144 Report of proposed sale of securities
• 06.04.2025 - 144/A Report of proposed sale of securities
• 06.02.2025 - EX-99.1 EX-99.1